Literature DB >> 33427654

CCTG SC.24/TROG 17.06: A Randomized Phase II/III Study Comparing 24Gy in 2 Stereotactic Body Radiotherapy (SBRT) Fractions Versus 20Gy in 5 Conventional Palliative Radiotherapy (CRT) Fractions for Patients with Painful Spinal Metastases.

A Sahgal1, S D Myrehaug2, S Siva3, L Masucci4, M C Foote5, M Brundage6, J Butler7, E Chow2, M G Fehlings8, Z Gabos9, J Greenspoon10, M Kerba11, Y K Lee12, M C Liu13, P Maralani14, I Thibault15, R Wong16, M Hum17, K Ding18, W Parulekar17.   

Abstract

Entities:  

Year:  2020        PMID： 33427654     DOI： 10.1016/j.ijrobp.2020.09.019

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN： 0360-3016            Impact factor:   7.038


× No keyword cloud information.
  9 in total

1.  Stereotactic ablative radiation therapy for spinal metastases: experience at a single Brazilian institution.

Authors:  Gustavo N Marta; Fernando F de Arruda; Fabiana A Miranda; Alice R N S Silva; Wellington F P Neves-Junior; Anselmo Mancini; Samir A Hanna; Carlos E C V Abreu; João Luis F da Silva; Jose Eduardo V Nascimento; Cecília Maria K Haddad; Fabio Y Moraes; Rafael Gadia
Journal:  Rep Pract Oncol Radiother       Date:  2021-09-30

2.  Are 5-Year Randomized Clinical Trial Results Sufficient for Implementation of Short-Course Whole Breast Radiation Therapy?

Authors:  Erin F Gillespie; Atif J Khan; Oren Cahlon; Lior Z Braunstein
Journal:  Pract Radiat Oncol       Date:  2021 Sep-Oct

3.  Multidisciplinary Treatment of Non-Spine Bone Metastases: Results of a Modified Delphi Consensus Process.

Authors:  Erin F Gillespie; Noah J Mathis; Max Vaynrub; Ernesto Santos Martin; Rupesh Kotecha; Joseph Panoff; Andrew L Salner; Alyson F McIntosh; Ranju Gupta; Amitabh Gulati; Divya Yerramilli; Amy J Xu; Meredith Bartelstein; David M Guttmann; Yoshiya J Yamada; Diana Lin; Kaitlyn Lapen; Deborah Korenstein; David G Pfister; Allison Lipitz-Snyderman; Jonathan T Yang
Journal:  Clin Transl Radiat Oncol       Date:  2022-04-26

4.  [Single dose of 24 Gy or 3-fraction SBRT regimen in the treatment of oligometastatic cancer? : A phase III multi-center trial].

Authors:  Hossein Hemmatazad; Etienne Mathier; Daniel M Aebersold; Mohamed Shelan
Journal:  Strahlenther Onkol       Date:  2021-06-29       Impact factor: 3.621

5.  Clinical Outcomes of Dose-Escalated Hypofractionated External Beam Radiation Therapy (5 Gy × 5 Fractions) for Spine Metastasis.

Authors:  Jacob Y Shin; Noah J Mathis; Neil Ari Wijetunga; Divya Yerramilli; Daniel S Higginson; Adam M Schmitt; Daniel R Gomez; Yoshiya J Yamada; Jonathan T Yang
Journal:  Adv Radiat Oncol       Date:  2022-02-04

6.  Local control of 1-5 fraction radiotherapy regimens for spinal metastases: an analysis of the impacts of biologically effective dose and primary histology.

Authors:  Roman O Kowalchuk; David Cousins; Kelly M Spencer; K Martin Richardson; James M Larner; Timothy N Showalter; William H McAllister; Jason P Sheehan; C Ronald Kersh; Sunil W Dutta
Journal:  Rep Pract Oncol Radiother       Date:  2021-12-30

7.  Retrospective analysis of characteristics associated with higher-value radiotherapy episodes of care for bone metastases in Medicare fee-for-service beneficiaries.

Authors:  Deborah Marshall; Melissa D Aldridge; Kavita Dharmarajan
Journal:  BMJ Open       Date:  2021-10-19       Impact factor: 2.692

8.  Reduction of inter-observer differences in the delineation of the target in spinal metastases SBRT using an automatic contouring dedicated system.

Authors:  Niccolò Giaj-Levra; Vanessa Figlia; Francesco Cuccia; Rosario Mazzola; Luca Nicosia; Francesco Ricchetti; Michele Rigo; Giorgio Attinà; Claudio Vitale; Gianluisa Sicignano; Antonio De Simone; Stefania Naccarato; Ruggero Ruggieri; Filippo Alongi
Journal:  Radiat Oncol       Date:  2021-10-09       Impact factor: 3.481

9.  Stereotactic body radiotherapy for osseous low alpha-beta resistant metastases for pain relief-SOLAR-P.

Authors:  Eric K Nguyen; Kimmen Quan; Sameer Parpia; Stephan Tran; Anand Swaminath
Journal:  Radiat Oncol       Date:  2021-09-03       Impact factor: 3.481
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.